Clinical trial
An Observational Study Utilising Data From EU National MS Registries to Estimate the Incidence of Anti-Natalizumab Antibody Among Patients Who Receive Subcutaneous Administration of Natalizumab for Treatment of RRMS
NCT05925049 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Study Utilising Data From EU National MS Registries to Estimate the Incidence of Anti-Natalizumab Antibody Among Patients Who Receive Subcutaneous Administration of Natalizumab for Treatment of RRMS
- Lead sponsor
- Biogen
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- June 30, 2023
- Completion date
- October 31, 2026
- Enrollment
- 400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.